VIJAYANSE4 February 2022

Vijaya Diagnostic Centre Limited has informed the Exchange about Investor Presentation

Vijaya Diagnostic Centre Limited

February 4, 2022

To, Listing Department National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400 051 Company Code No. VIJAYA

To, The Corporate Relations Department BSE Limited, Phiroz Jeejeebhoy Towers, 25th Floor, Dalal Street Mumbai- 400 001 Company Code No. 543350

Dear Sir/Madam,

Sub: Investor Presentation.

Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the presentation that would be used in the Investors / Analysts call scheduled to be held on February 8, 2022 at 4.00 pm IST.

Please take the information on record.

Thanking you,

For Vijaya Diagnostic Centre Limited

Anusha Kanumuru Company Secretary

Vijaya Diagnostic Centre Limited

Investor Presentation

Q3 & 9MFY22

Safe Harbour

This presentation and the accompanying slides (the “Presentation”), which have been prepared by Vijaya Diagnostic Centre Limited (the ‘Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.

Q3 & 9MFY22 Financial Performance

Q3 & 9MFY22 – Performance Snapshot

Operational & Financial Highlights – Q3 FY22

Operational & Financial Highlights – 9M FY22

2.32 Mn Tests

0.85 Mn Footfalls

89 Centres (opened 4)

95% B2C Revenue

INR 1,107.8 Mn Revenue

INR 478.3 Mn EBIDTA

43.2% EBIDTA Margin

INR 252.9 Mn Profit After Tax

22.8% PAT Margin

6.87 Mn Tests

2.67 Mn Footfalls

89 Centres (opened 9)

94% B2C Revenue

INR 3,461.7 Mn Revenue

INR 1,558.3 Mn EBIDTA

45.0% EBIDTA Margin

INR 859.7 Mn Profit After Tax

24.8% PAT Margin

Key Operational Highlights (1/2)

Annual

YTD

Quarterly

6.99

7.91

7.09

Tests Performed (# in Million)

46%

6.87

4.71

22% Y-o-Y

2.36

2.32

1.91

FY19

FY20

FY21

9MFY21

9MFY22

Q3FY21

Q2FY22

Q3FY22

2.38

2.79

2.63

Footfalls (# in Million)

53%

2.67

1.75

0.68

25% Y-o-Y

0.87

0.85

FY19

FY20

FY21

9MFY21

9MFY22

Q3FY21

Q2FY22

Q3FY22

Key Operational Highlights (2/2)

Annual

YTD

Revenue per Test (INR)

Quarterly

419

428

531

562

504

524

COVID effect: In-line with historical years 477

477

FY19

FY20

FY21

9MFY21

9MFY22

Q3FY21

Q2FY22

Q3FY22

Revenue per Footfall (INR)

1,431

1,299

1,515

1,463

COVID effect: In-line with historical years 1,303

1,295

1,228

1,214

FY19

FY20

FY21

9MFY21

9MFY22

Q3FY21

Q2FY22

Q3FY22

Revenue – COVID, COVID Allied and Non-COVID

(INR Mn)

Annual

2,926

3,388

3,123

YTD

Non-COVID Revenue

39%

2,947

2,121

Quarterly

20% Y-o-Y

1,019

1,022

855

FY19

FY20

FY21

9MFY21

9MFY22

Q3FY21

Q2FY22

Q3FY22

% of Revenue

17.1%

19.9%

14.9%

14.4%

9.6%

7.8%

COVID & COVID Allied Revenue*

644

109

535

FY21

526

439

514

149

365

144

116

40% Y-o-Y

108

86 10

9MFY21

9MFY22

Q3FY21

Q2FY22

Q3FY22

COVID

COVID Allied

*COVID revenue includes RT-PCR, Antibody tests and COVID Allied tests like IL-6 and D- Dimer

0 FY19

0 FY20

Key Financial Highlights (1/2)

(INR Mn)

Annual

YTD

Quarterly

3,388

3,767

2,926

Revenue from Operations

31%

3,462

2,647

11% Y-o-Y

1,127

1,108

999

FY19

FY20

FY21

9MFY21

9MFY22

Q3FY21

Q2FY22

Q3FY22

EBITDA & EBITDA Margin (%)

37.0%

39.1%

44.1%

42.1%

45.0%

1,081

1,326

1,660

40%

1,558

1,116

46.5%

464

45.4%

3% Y-o-Y

511

43.2%

478

FY19

FY20

FY21

9MFY21

9MFY22

Q3FY21

Q2FY22

Q3FY22

15.7%

18.5%

22.4%

459

625

843

PAT & PAT Margin (%)

20.0%

531

62%

24.8%

860

24.8%

247

24.6%

2% Y-o-Y 277

22.8%

253

FY19

FY20

FY21

9MFY21

9MFY22

Q3FY21

Q2FY22

Q3FY22

Key Financial Highlights (2/2)

Annual

YTD

Cash Flow from Operations / EBITDA (%)

84%

80%

78%

81%

77%

FY19

FY20

FY21

9MFY21

9MFY22

Cash & Cash Equivalents (INR Mn)

1,729

2,277

1,215

2,069

2,349

FY19

FY20

FY21

9MFY21

9MFY22

Working Capital Days

FY19

FY20

FY21

9MFY21

9MFY22

-13

-12

-13

-16

-10

Cash & Cash Equivalents: Cash + Bank Balance + Current investments + FDs with more than 12 months Maturity; Working Capital days: Inventory days + Receivable days – Payable days; Inventory days: Inventory at end of respective period / respective financial year Revenue or Last 12 months Revenue; Receivable days: Receivables at end of respective period / respective financial year Revenue or Last 12 months revenue; Payable days: Payables at end of respective period / respective financial year revenue or Last 12 months revenue; Cash Flow from operations for H1FY22 is adjusted for share issue expense receivables

Consolidated Profit & Loss Account – Q3 & 9MFY22

(INR Mn)

Particulars

Revenue from operations

Cost of materials consumed

Employee benefits expense

Other expenses

EBITDA

EBITDA Margin (%)

Other income

Depreciation and amortization expense

EBIT

Finance costs

Profit before Tax

Tax expenses

Profit before Minority Interest

Minority Interest

Profit after Tax (PAT)

PAT Margin (%)

EPS – Basic (INR)*

Q3FY22

1,107.8

163.0

182.2

284.3

478.3

43.2%

32.0

130.1

380.2

41.8

338.5

83.9

254.6

1.7

252.9

22.8%

2.48

Q3FY21

Y-o-Y

11%

17%

20%

17%

16%

-45%

998.8

139.8

151.8

243.0

464.3

46.5%

29.9

125.0

369.1

36.0

333.1

82.6

250.5

3.2

247.3

24.8%

2.43

Q2FY22

1,127.1

162.4

171.0

282.3

511.5

45.4%

31.5

124.8

418.3

39.4

378.9

98.9

280.0

2.9

277.1

24.6%

2.72

Q-o-Q

-2%

-6%

-9%

-11%

-15%

-9%

-39%

-9%

9MFY22

3,461.7

536.2

514.6

852.5

9MFY21

2,647.4

408.3

422.6

700.9

1,558.3

1,115.6

45.0%

96.4

374.1

1,280.7

121.2

1,159.5

291.7

867.8

8.2

859.7

24.8%

8.43

42.1%

76.4

379.0

813.0

117.8

695.2

160.7

534.5

3.8

530.6

20.0%

5.20

Y-o-Y

31%

22%

40%

26%

-1%

58%

67%

81%

62%

113%

62%

*Not annualized

Company Overview

Vijaya at a Glance

Vijaya Diagnostic Centre Limited is the largest integrated diagnostic chain in South India with 89 state-of-the-art centres spread across 15 cities

Mission

Our Mission is to make the patient’s medical journey faster, more transparent and more accurate. We are committed to deliver exceptional diagnostic solutions to every patient and physician

40+ Years of Experience

Experience in delivering Quality Diagnostic Service at affordable prices

89 Centres

State-of-the-art Facilities with Best-in-class Technology

15 Cities across India

~200 Doctors

Vision

Largest integrated player in South India

Radiologists, Pathologists & Microbiologists

Our Vision is to provide reliable and accurate to our customers, at diagnostic services customer-centric in a affordable prices, manner. We strive to provide the best service possible. We are continually raising our own bar through the latest technology, continuous improvement and recruitment of high calibre technicians and professional

~3.6 Mn Footfalls

~9.2 Mn Tests

Trusted by every Age group

Most preferred Diagnostic Centre

Footfalls & Tests for 12 months ending Dec 2021

Quality

Reliable & Accurate Diagnostics

at Affordable Prices

Our Journey

Vijaya Diagnostic Centre incorporated in Hyderabad

Recognized as one of the Best Imaging centres in Hyderabad by The Week

Awarded Brand of the year in diagnostic services by The CEO Magazine and Telangana Healthcare Leadership award

One of the earliest private diagnostic service providers to be approved for COVID RT-PCR testing by ICMR*

1981

2012

2018

2020

2008

2016

2019

2021

First independent diagnostic centre in South India to offer PET CT from Wipro GE Healthcare Pvt. Ltd.

Investment by Karakoram Limited and Kedaara Capital Alternative Investment Fund – Kedaara Capital AIF1

Awarded Best Diagnostic Centre – India by Times Healthcare Achievers Group

Successfully listed on Indian Stock Exchanges (NSE & BSE)

First independent diagnostic centre in Telangana to get Revolution ACT 50 slice CT from Wipro GE Healthcare Pvt. Ltd

*ICMR: Indian Council of Medical Research; NSE: National Stock Exchange, BSE: Bombay Stock Exchange

At the Forefront of Introducing New Technologies

1981

Ultrasound & Echocardiography

1986

Nuclear Medicine facility

1993

Fourth Generation CT Scan

1994

Offer Mammography

2006

Hawkeye Gamma Camera with SPECT

2003

Automated Microbiology Culture

2000

Real Time RT-PCR Assays & Flow Cytometry

1999

Bone Densitometry

2007

Cardiac CT & 3.0 Tesla MRI

2009

HPV-DNA HC2 test in South India

2011

Automated TB identification & Sensitivity in South India

2012

Liquid Based Cytology (Thin Prep) in Andhra Pradesh (AP)

2019

3D Mammography with Advanced Technology

2019

USG-ECHO for Cardiology & Advanced CBCT in South India

2017

Droplet Digital PCR (ddPCR) & Adv. PET CT in South India

2013

Iris iQ200 Automated with Analyzer Urine Microscopy & Siemen’s Accuson Elastography

2019

DNA fragmentation Index test in semen

2020

Integrated modular solution for Immunoassay & Chemistry assays

2020

COVID testing by RT-PCR in Telangana & AP

2021

Philips DS Achieva with Ambient Experience

Our Pillars of Strength

One of the leading players in India’s high growth diagnostics market

Integrated diagnostics provider offering one-stop solution

High brand recall driving customer stickiness

Robust technical capabilities and state-of-the-art technology

Experienced Board and strong management team

Indian Diagnostics Market expected to Grow at a Healthy Trajectory

Indian Diagnostics Market

Segment-wise breakup of Indian Diagnostic Market

(INR Bn)

Radiology

Pathology

980

+13% CAGR

684

472

FY17

FY20

FY23E

+13% CAGR

FY23E 275 - 285

FY20 190 - 195

South India

27% - 29%

FY20

71%-73%

Rest of India

980

43% - 44%

684

43%

+13% - 14% CAGR

+14% CAGR

56% - 57%

+12% CAGR

57%

+12% - 13% CAGR

FY20

FY23E

472

41%

59%

FY17

Source: CRISIL Report

One of the leading players in India’s high growth diagnostics market

Telangana and Andhra Pradesh Market Size

Vijaya’s Core Geographies

Telangana and Andhra Pradesh (44 - 46% of South India)

+14% CAGR

(INR Bn)

120 -130

FY17

FY20

FY23E

Growth Drivers:

•

Rising NCDs in the states

Increasing share of aged population

Rising health awareness

Increasing health insurance penetration

Conducive government healthcare schemes

Dominant Position in Telangana & Andhra Pradesh

Karimnagar

Mancherial

Hanamkonda Kazipet

Warangal

Nizamabad

Sangareddy

Hyderabad & Secunderabad

Vishakhapatnam

Kurnool

Nandyal

Nellore

NCD: Non Communicable diseases

Source: CRISIL Report

Integrated Diagnostic service provider with extensive network…

Customers

Samples

Customer (Walk-in) Home Collection B2B Hospitals & Labs

National Reference Lab

Reference Lab

#11

Sample Flow Patient Flow

Vijaya Diagnostic Centre

Flagship Centre #1

Hubs #23

Diagnostic Centres / Spokes #65

Flagship Centre = Lab Sample Collection + Basic Radiology + Complete Advanced Radiology (MRI, CT Scan, SPECT & PET CT) Hubs = Lab Samples Collection + Basic Radiology + Advanced Radiology (MRI / CT Scan / SPECT) Diagnostic Centre / spokes = Lab Samples Collection + Basic Radiology Basic Radiology = ECG / X-ray / USG / Mammography / BMD / TMT / 2D Echo / EEG / ENMG / Endoscopy, etc.

…offering One-Stop Solutions for Pathology & Radiology

Complete Range of Diagnostic Services under One Roof Comprehensive and high quality integrated diagnostic services through our operational network

High brand recall driving customer stickiness

Customer Centric Approach

Quality Diagnostic Services

B2C Revenue

Higher brand recall

High share of walk-in customers

Sticky individual customer

“One of the Best Healthcare Brands 2021” by The Economic Times in 2021

“For excellence in Quality and Accuracy” under the category Leading Diagnostics company with Excellence in Quality and Safety at the Diagnostics Leadership Summit in 2021

90.0%

93.0%

92.0%

FY19

FY20

FY21

Operational Metrics

(INR)

1,228

1,214

454

475

1,431

631

FY19 Revenue per footfall

FY20

FY21

EBITDA per footfall

Robust Technical Capabilities with State-of-the-art IT Infrastructure

CT Machines

MRI Machines

PET CT / Gamma machines

198

Radiologists, Lab Doctors & Physicians

NABH Accreditations

NABL Accreditations

Key Suppliers

• Long standing relationship with medical technology vendors

• At the forefront of introducing new tests by

adopting the latest medical

technologies

• Among the first diagnostic service provider in South India to offer PET-CT scan

in 2008

Advanced Software to Manage Clinical Data

Advance Laboratory Information Management System (LIMS)

Fully Integrated Radiology Information Systems (RIS) and Picture Archive and Communication Systems (PACS)

Front end IT infrastructure enabling…

Standardization across our operations

incidence

Reduce errors due Human Intervention

of Low

Monitor Operations

Technical

Closely track key performance metrics and maintain the Turn- Around Time (TAT)

Provide Uniform Experience to booking from customers accessing to appointments reports online

Experienced Board of Directors

Dr. S Surendranath Reddy - Executive Chairman  Founder of Vijaya with 40+ years of experience in building Vijaya as South

India’s largest integrated diagnostic chain

 Holds Bachelor’s degree in Medicine and Provisional degree of Doctor of

Medicine in Radiology

Dr. D Nageshwar Reddy - Non-executive, Independent Director

 Chairman of Asian Institute of Gastroenterology (AIG), Hyderabad  Awarded Padma Shri and Padma Bhushan by Government of India  D.M in Gastroenterology from PGIMER Chandigarh

S Geeta Reddy - Non-Executive Director

Shekhar Prasad Singh - Non-executive, Independent Director

 Enrolled as advocate with Andhra Pradesh High Court in 1986

 Holds a Bachelor’s degree in Law from Osmania University

 Ex-Chief Secretary to Government of Telangana

 Retired IAS officer of 1983 batch

Sunil Chandra Kondapally - Executive Director

Satyanaryana Murthy Chavali - Non-executive, Independent Director

 Been with Vijaya since 2002 and 17+ years of experience in healthcare

 Holds Bachelor’s degree in Electrical Engineering from Florida State

University

 Ex-CEO of Aurigene Discovery Technologies Ltd.

 Holds BTech from IIT, Madras and MBA from IIM, Bangalore

Nishant Sharma - Non-executive, Nominee Director

Dr. Manjula Anagani - Non-executive, Independent Director

 18+ years of experience; CIO and Managing Partner at Kedaara Capital  Holds Master’s degree in Biochemical Engineering and Biotechnology from

Indian Institute of Technology, Delhi

 MBA from Harvard University

 Clinical Director and Head of Department of centre of women and childcare at

Care hospitals

 Awarded Padma Shri by Government of India  MD in Obstetrics and Gynecology from N.T.R. University of Health Sciences

Strong Management Team

Dr. S. Surendranath Reddy

Mr. Sunil Chandra Kondapally

Ms. Suprita Reddy

Mr. Narasimha Raju K.A

Ms. Anusha Kanumuru

Executive Chairman

Executive Director

Chief Executive Officer

Chief Financial Officer

Company Secretary & Compliance Officer

 40+ years of experience in building Vijaya as South India’s integrated diagnostic largest chain

 Holds Bachelor’s degree in Provisional and Medicine degree of Doctor of Medicine in Radiology

 He is a life member of the and

Radiological

Indian Imaging Association.

 With Vijaya since incorporation and experienced in operations, finance, quality accreditation, marketing network expansion departments

and

 17+ Years of experience in healthcare industry & founded Trikona Pharmaceuticals Pvt. Ltd. (2016) and QPS Bioserve India Pvt. Ltd. (2004)

operations

 With Vijaya since 2003 and heads overall strategy, clinical and excellence, expansion of the company  Awarded Women Leadership Award in Healthcare by ABP in 2019

 Holds bachelors degree in from Osmania

commerce University

 Holds bachelor’s degree

electrical engineering Florida State University

in from

 Associated with Vijaya from June 2017 to Nov 2020 and rejoined in March 2021

 14+ years of experience in reporting, financial and

audit, regulatory accounting advisory

compliance

 Previously worked with SR Baltliboi & Co., NSL Renewable Power Pvt. Ltd. etc

 Holds bachelor’s degree of commerce from Osmania University and member of the Chartered of Institute Accountants of India

 12+ years of experience in secretarial, FEMA and legal compliance  Previously

worked

with IVRCL Ltd,

Aurobindo Realty, Brightcom Group

company and

 Associate member of institute secretaries of Bachelor and

of India degree corporate affairs

holds in commerce

Awards & Accolades

One of the Best Healthcare Brands 2021

Indo Global Award for Healthcare Excellence

Company of the Year - Healthcare

Leading Diagnostic Chain of the Year

India’s Greatest Leaders 2020-21 Ms. Suprita Reddy - CEO

2021 Presented by The Economic Times

2021 Presented by Indian Economic Development & Research Association

2021 Presented by TV9 Network and SAP

2021 Presented by Diagnostic Leadership Summit

2021 Presented by United Research Services

India’s Greatest Brands 2020-21 Pride of Nation

Leading Diagnostics with Excellence in Quality & Safety

Most Trusted and Best Quality Diagnostic services in India

Healthcare Entrepreneur of the Year – Dr. Surendra Reddy

Fastest Growing Brands (Pride of the Nation)

2021 Presented by United Research Services

2021 Presented by Diagnostic Leadership Summit

2020 Presented by Times Healthcare Achievers

2019 Presented by Six Sigma Healthcare

2019 Presented by United Research Services

Best Diagnostic Centre of the Year

Leading Chain of Diagnostics & Imaging

Best Diagnostic Service Provider of the Year

Most Trusted Diagnostic Centre of the Year

Telangana Healthcare Leadership Awards

2019 Presented by Times Healthcare Achievers

2019 Presented by Indian Medical Association, Telangana state and Messe India

2019 Presented by Six Sigma Healthcare

2019 Presented by Indo-Arab Leaders Summit & Awards

2018 Presented by Telangana Government

Shareholding Pattern

Others

3.9%

16.7%

14.6%

10.0%

FII’s

DII’s

Promoter & Promoter group

54.8%

Kedaara Capital*

Shareholding Pattern as of 31st December 2021

Category

Kedaara Capital*

Fidelity Group#^

Axis Mutual Fund^

Aberdeen Standard Investments^

Nippon Life India Asset Management^

Mirae Asset Mutual Fund^

Aditya Birla Sun Life Asset Management^

Abu Dhabi Investment Authority

DSP Mutual Fund

% Holding

10.0%

6.6%

6.3%

4.6%

1.9%

1.8%

1.7%

1.0%

As on 31st Dec 2021 DII’s: Mutual Funds, AIF’s and QIB’s Others: Retail, Bodies Corporate and others

* includes Karakoram Limited and Kedaara Capital AIF ^holding through various schemes/funds # Fidelity International Limited (FIL) and Fidelity Management and Research Company (FMR)

Strategy Going Forward

Deepen Footprint in our Core Markets - Telangana & Andhra Pradesh

Nizamabad

Sangareddy

Mancherial

Karimnagar

Hanamkonda Kazipet Warangal

Hyderabad & Secunderabad

Vishakhapatnam

Kurnool

Nandyal

Nellore

Leveraging Existing Presence

Given under-penetration of diagnostic market, we will continue to focus on

Opening additional diagnostic centres through owned & franchisee model

Expanding network through setting up spokes and hubs in existing catchment areas

Adding reference laboratories in our existing core geographies

Consolidate Leading Position

Given our significant presence and operational experience in Telangana and Andhra Pradesh, we intend to deepen our penetration and increase customer base by

Enhancing laboratory capacity and test menu by adding latest technologies

Offering value added services

Physician engagements (by conducting continuous medical education programs)

Expand in Adjacent Geographies & East India

Network (9MFY22)

South India Strategy

 Expand in concentric circles given our

hub and spoke model

 Establish presence in adjacent

geographies

 Identified key cities and towns which are

underserved and our brand is well- regarded

 Wider geographic reach will expand our

customer base leading to better profitability by leveraging our infrastructure

Hyderabad

Rest of Telangana and AP

Others

East India Strategy

 Expand presence in East India given

growing demand

 Replicate our successful hub and spokes

model in East India

 Established a hub in Kolkata and plan is to

set up additional diagnostic centres around it

 Hence, Kolkata to be our focus area for

medium to long term growth

AP: Andhra Pradesh

Continued Focus on Providing Customer Centric Services and Offerings

Preventive and Wellness Testing to Boost Demand for Diagnostics

FY20E

Industry Size

FY23P

CAGR: ~20%

101-108

61-68

Rest of the market 90%

Wellness & Preventive 9% - 10%

Wellness & Preventive 11%

Rest of the market 89%

FY20

FY23

Key Drivers

Our Strategy

 Increasing chronic and lifestyle diseases

 Increase diagnostic services by offering additional preventive and wellness services through adoption of

new cutting-edge diagnostic testing technology

 Corporate tie-ups

 Increasing disposable income

 Increasing service offerings

 Providing home collection services and point-of-contact testing to complement walk-in

 Expand specialty tests, disease specific profiles and provide customized packages

 Grow our corporate customer base by catering to their needs

 Expansion of chronic disease management and wellness programs

Source: CRISIL Report

Financial & Operational Highlights

Robust Operational Metrics

Diagnostic Centre (Nos)

Footfalls (Mn)

Tests Performed (Mn)

Impact of Covid- 19 on Walk-in Customers

2.38

2.79

2.63

6.99

7.91

Impact of Covid-19

7.09

FY19

FY20

FY21

FY19

FY20

FY21

FY19

FY20

FY21

Test per Footfall (Nos)

Revenue per Test (INR)

Revenue per Footfall (INR)

2.93

2.83

2.69

419

428

531

1,228

1,214

1,431

FY19

FY20

FY21

FY19

FY20

FY21

FY19

FY20

FY21

Consistent Financial Performance

(INR Mn)

Revenue

EBIDTA

PAT

CAGR:13%

3,388

3,767

2,926

CAGR:24%

1,660

1,326

1,081

CAGR:36%

843

625

459

FY19

FY20

FY21

FY19

FY20

FY21

FY19

FY20

FY21

EBIDTA Margin (%)

PAT Margin (%)

710 bps

39.1%

44.1%

37.0%

670 bps

18.5%

22.4%

15.7%

FY19

FY20

FY21

FY19

FY20

FY21

Sustainable Cash Generation & Increasing Return Ratios

Cash & Cash Equivalents

CFO / EBIDTA (%)

2,277

1,729

84%

80%

78%

(INR Mn)

1,215

FY19

FY20

FY21

FY19

FY20

FY21

RoCE Pre-Cash (%)

RoE (%)

30%

33%

43%

22%

23%

FY19

FY20

FY21

FY19

FY20

FY21

ROCE (Pre-cash): PBIT ex Other income / (Total Assets – Cash – Current Liabilities)

CFO = Cash flow from Operations

Annexure

Consolidated Profit & Loss Account

(INR Mn)

Particulars

Revenue from operations

Cost of materials consumed

Employee benefits expense

Other expenses

EBITDA

EBITDA %

Other income

Depreciation and amortization expense

EBIT

Finance costs

Profit before Tax

Tax expenses

Profit after Tax before Minority Interest

Minority Interest

Profit after Tax

PAT %

EPS – Basic (INR)

9MFY22

3,462

536

515

853

1,558

45.0%

374

1,281

121

1,160

292

868

860

24.8%

8.43

FY21

3,767

571

574

962

1,660

44.1%

118

505

1,273

152

1,121

272

849

843

22.4%

8.26

FY20

3,388

439

624

999

1,326

39.1%

154

492

988

154

834

209

625

18.5%

6.13

FY19

2,926

405

539

901

1,081

36.9%

104

396

789

135

654

190

464

459

15.7%

4.50

Consolidated Balance Sheet

(INR Mn)

Assets

Sep-21 Mar-21 Mar-20 Mar-19

EQUITY AND LIABILITIES

Sep-21 Mar-21 Mar-20 Mar-19

NON-CURRENT ASSETS Property, plant and equipment Capital work-in-progress Goodwill Other intangible assets Right of use asset Intangible assets under development Financial assets - Investments - Other financial assets Deferred tax assets Income tax assets Other assets

CURRENT ASSETS Inventories Financial assets - Investments - Trade receivables - Cash and cash equivalents - Bank balances other than Cash and cash equivalents - Loans - Other financial assets Other current assets

3,954 1,660 159 53 14 1,529 4

0 165 77 3 291

3,021 1,358 82 53 6 1,260 12

0 122 61 6 61

2,959 1,398 93 53 10 1,254 4

0 55 16 9 67

2,689 1,437 27 69 7 1,079 -

0 43 12 8 7

2,521 53

2,388 26

1,865 28

1,374 22

283 67 286

276 64 67

1,619

1,876

- 168 45

3 49 27

547 80 556

626

1 5 22

688 91 96

430

4 26 17

EQUITY

Equity share capital

Instruments entirely equity in nature

Other equity

4,212

102

3,592

2,741

2,069

4,110

3,547

2,696

2,000

NON-CURRENT LIABILITIES

1,618

1,378

1,494

1,422

Financial liabilities

- Borrowings

- Lease liabilities

- Other financial liabilities

Provisions

Other liabilities

CURRENT LIABILITIES

Financial liabilities

- Borrowings

- Lease liabilities

- Trade payables

- Other financial liabilities

Income tax liabilities

Provisions

Other liabilities

1,543

1,265

221

1,196

315

1,034

646

439

589

572

114

258

137

101

222

217

224

218

204

TOTAL ASSETS

6,476

5,409

4,824

4,063

TOTAL EQUITY AND LIABILITIES

6,476

5,409

4,824

4,063

Consolidated Cash Flow Statement

(INR Mn)

Particulars Cash Flow from Operating Activities Profit before Tax Adjustment for Non-Operating Items Operating Profit before Working Capital Changes Changes in Working Capital Cash Generated from Operations Less: Direct Taxes paid Net Cash from Operating Activities Purchase and construction of property, plant and building (net) Investments (net) Others Cash Flow from Investing Activities Cash Flow from Financing Activities Net increase/ (decrease) in Cash & Cash equivalent Cash & Cash Equivalents at the beginning of the period Cash & Cash equivalents at the end of the period

Cash and Cash Equivalents

Particulars

Investments*

Cash and cash equivalents

Bank balances other than Cash and cash equivalents

Total

Sep-21

Mar-21

Mar-20

Mar-19

821 260 1,081 -86 995 -156 839 -729 218 62 -450 -170 219 67 286

Sep-21

380

286

1,619

2,286

1,121 534 1,655 -46 1,609 -312 1,297 -312 -1,033 47 -1,298 -488 -489 556 67

834 492 1,326 -32 1,294 -233 1,061 -375 11 57 -306 -295 460 96 556

653 431 1,084 8 1,092 -187 905 -591 -314 6 -898 -72 -65 161 96

Mar-21

Mar-20

Mar-19

335

1,876

2,277

547

556

626

1,729

688

430

1,215

*Current investments + investments with maturity more than 12 months (part of other non-current financial assets)

THANK YOU

Company

Investor Relations Advisors

Vijaya Diagnostic Centre Limited (VDCL)

Orient Capital (a division of Link Group)

Mr. Krishna Kiran – Investor Relations +91 90597 00749

krishnakiran@vijayadiagnostic.in ir@vijayadiagnostic.in

www.vijayadiagnostic.com

Ms. Ashish Chovatia : +91 99300 44680 Ashish.chovatia@linkintime.co.in

Ms. Payal Dave: +91 98199 16314 payal.dave@linkintime.co.in

#6-3-883/F, Ground Floor, FPAI Building, Punjagutta, Officers Colony, Near Topaz Building, Hyderabad-500082, Telangana, India.

← All Transcripts VIJAYA Stock Page →

Vijaya Diagnostic Centre Limited has informed the Exchange about Investor Presentation

Market Movers